- Home
- UPB vs BNTC Comparison
UPB vs BNTC Comparison
Compare UPB & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPB
- BNTC
- Stock Information
- Founded
- UPB 2021
- BNTC 1995
- Country
- UPB United States
- BNTC United States
- Employees
- UPB N/A
- BNTC 16
- Industry
- UPB
- BNTC Biotechnology: Pharmaceutical Preparations
- Sector
- UPB
- BNTC Health Care
- Exchange
- UPB NYSE
- BNTC Nasdaq
- Market Cap
- UPB 402.8M
- BNTC 322.6M
- IPO Year
- UPB 2024
- BNTC N/A
- Fundamental
- Price
- UPB $8.78
- BNTC $13.75
- Analyst Decision
- UPB Strong Buy
- BNTC Strong Buy
- Analyst Count
- UPB 4
- BNTC 7
- Target Price
- UPB $56.50
- BNTC $24.71
- AVG Volume (30 Days)
- UPB 305.5K
- BNTC 64.1K
- Earning Date
- UPB 05-14-2025
- BNTC 05-12-2025
- Dividend Yield
- UPB N/A
- BNTC N/A
- EPS Growth
- UPB N/A
- BNTC N/A
- EPS
- UPB N/A
- BNTC N/A
- Revenue
- UPB $2,370,000.00
- BNTC N/A
- Revenue This Year
- UPB N/A
- BNTC N/A
- Revenue Next Year
- UPB $0.99
- BNTC N/A
- P/E Ratio
- UPB N/A
- BNTC N/A
- Revenue Growth
- UPB N/A
- BNTC N/A
- 52 Week Low
- UPB $5.14
- BNTC $5.08
- 52 Week High
- UPB $29.46
- BNTC $16.90
- Technical
- Relative Strength Index (RSI)
- UPB N/A
- BNTC 55.16
- Support Level
- UPB N/A
- BNTC $13.26
- Resistance Level
- UPB N/A
- BNTC $14.22
- Average True Range (ATR)
- UPB 0.00
- BNTC 1.37
- MACD
- UPB 0.00
- BNTC 0.08
- Stochastic Oscillator
- UPB 0.00
- BNTC 87.27
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.